Regenerative Medical Technology grows revenue, ramps Cancun ops amid heavy debt and defaults

Regenerative Medical Technology Group Inc. (PINK: MSSV) - concise internal readout.

What's happening inside:
The company is scaling Global Stem Cells Group operations (training, product sales, patient procedures) and ramping manufacturing at its Cancún facility while signing clinic expansion and affiliate partnership deals. Revenues are rising, but the balance sheet is stressed by large promissory notes in default, heavy accrued interest and ongoing debt restructurings. Management warns of a going concern and is pursuing debt extensions and new financing.

Income statement - positives
* Revenue growth: +45.80% for six months - $2,347,859 (6M 2025) vs $1,610,363 (6M 2024).
* Q2 revenue: $983,518 (Q2 2025) vs $793,329 (Q2 2024) - +23.97%.
* Gross profit (6M 2025): $1,529,726; Gross margin 65.15% for the period (Global Stem Cells Group segment).
* Operating loss narrowed (6M): $(115,127) in 2025 vs $(319,086) in 2024 - operating performance improving.
* Cash increased: $1,614,254 at June 30, 2025 (up $448,434 vs Dec 31, 2024) after a $1,100,000 financing in Q2.

Income statement & financials - negatives / risks
* Net loss: $(2,065,825) for six months ended June 30, 2025 (improved from $(4,037,640) prior year). Q2 net loss $(1,305,785).
* Heavy interest and financing costs: interest expense $1,949,221 (6M 2025) and $1,055,371 (Q2 2025).
* Accrued interest on balance sheet: $12,396,257 as of June 30, 2025.
* Promissory notes principal (aggregate): $21,105,731 (principal reported) and total promissory notes, net presented as $20,487,748 after discounts.
* Multiple notes are in default (examples): secured note $2,872,797 (in default, later restructured), $11,600,000 note (in default) with accrued interest $6,852,609, $1,000,000 note in default with accrued interest $914,548, $400,000 note with accrued interest $889,878 - significant default exposure disclosed.
* Working capital deficit: $28,630,295 as of June 30, 2025; accumulated deficit $69,618,927; total stockholders' deficit $(29,021,250).
* Cash burn from ops: net cash used by operating activities $(540,984) for six months ended June 30, 2025.
* Potential dilution and off‑balance financing: outstanding warrants 82,526,461 (quarter ended June 30, 2025); warrants and preferred stock issued with debt (warrants fair value $400,847; Series CC preferred fair value recorded $401).
* Going concern: management explicitly states substantial doubt about continuation without new capital or debt restructuring.
* Small derivative liability: $6,166 (June 30, 2025) and other fair-value volatility exposures noted.

Key balance sheet and operating metrics (selected)
* Total assets: $4,486,828 (June 30, 2025).
* Total liabilities: $33,508,078 (June 30, 2025).
* Cash & cash equivalents: $1,614,254 (June 30, 2025).
* Accounts receivable: $36,676; Inventory: $105,688; Prepaid expenses: $154,864.
* Goodwill: $1,679,978; Intangible assets, net: $110,234.
* Revenue by category (6M 2025): Training $279,885; Product supplies $1,030,089; Equipment $8,435; Patient procedures $1,029,450.
* Depreciation & amortization (6M): $106,646; operating expenses (6M): $1,644,853.
* Weighted average common shares: 12,538,968; net loss per share (6M): $(0.16).

Recent / subsequent actions and operational notes
* April 9, 2025 financing: Promissory debenture $1,375,000 (advanced $1,100,000 net) with one Series CC preferred share issued and warrants recorded (warrant fair value $400,847).
* August 14, 2025 extensions: Company agreed to extend maturities on several defaulted notes to July 31, 2026, in exchange for warrants (large warrant grants disclosed).
* Inventory setback: prepaid inventory of $100,000 failed testing; company pursuing refund (subsequent event disclosed).
* Clinic expansion and manufacturing ramp: Cancún manufacturing moving to full scale; planned clinic launches and affiliate deals in 2025-2026 highlighted in MD&A (Indonesia, Puerto Rico, Chile, Portugal, others).

Bottom line (straightforward)
The business shows real revenue traction and a healthy gross margin driven by product sales and patient procedures. However, the company is financially stressed - large promissory debt, multiple defaults, heavy accrued interest, a sizable working‑capital and stockholders' deficit, explicit going‑concern language and ongoing debt restructurings. Short-term survival depends on successful refinancing/debt restructuring, collection of cash from operations, or equity injections; expansion plans are contingent on securing that capital. Investors should weigh operational progress against acute liquidity and solvency risks.

Data source: Regenerative Medical Technology Group Inc. Form 10‑Q for quarter ended June 30, 2025 (figures quoted exactly as presented).